Age-related Macular Degeneration
Springer International Publishing (Verlag)
978-3-030-66013-0 (ISBN)
This edited book focuses on the recent advances in our understanding of age-related macular degeneration (AMD), combining epidemiology and clinical diagnosis, with genetics and immunological aspects as well as the role of proteostasis and mitochondria before diving into new therapies including stem cell based approaches.
AMD is a leading cause of largely incurable blindness worldwide and projected to double from 2.07 million to 5.44 million individuals by 2050 in the United States. Globally, 288 million individuals are projected to have AMD by 2040. The disease has enormous socioeconomic impact on the affected individuals, their families and the society. This book will bring together the state of the art basic science knowledge with clinically relevant findings and address the challenges for future research in AMD. The intersection of different disciplines will provide potential areas for further investigations to reduce the burden of blindness from AMD.
This book offers an appealing and insightful resource for clinicians, scientists, students and fellows.
lt;p>Emily Chew is the Director of the Division of Epidemiology and Clinical Applications (DECA), at the National Eye Institute, the National Institutes of Health in Bethesda, Maryland. She is also the Chief of the Clinical Trials Branch. Emily received her medical degree and her ophthalmology training at the U. of Toronto, School of Medicine, in Toronto, Canada. She completed her fellowship in Medical Retina at the Wilmer Eye Institute, the Johns Hopkins Medical Institutes and the U. of Nijmegen, the Netherlands.
Her research interest includes designing and conducting phase I/II;III clinical trials and epidemiologic studies in chronic retinovascular diseases such as age-related macular degeneration, diabetic retinopathy, the leading causes of blindness in the US. She was actively involved with leadership roles in the conduct of clinical trials such as Age-Related Eye Disease Study, the Age-Related Eye Disease Study 2, the Actions to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study, the Macular Telangiectasia Project (Mac Tel Project) with phase 1 to 3 clinical trials using ciliary neurotrophic factor (CNTF). She chairs the current international study, known as the AMD Ryan Initiative Study (ARIS), which evaluates the natural course of early AMD. She also collaborates with colleagues at the National Library of Medicine (NLM/NIH) utilizing of artificial intelligence/deep learning on the detection and progression of age-related macular degeneration.Emily Chew has been recognized for her scientific accomplishments, and mentoring efforts by the National Institutes of Health and numerous professional societies in the area of retinal research.
Dr. Anand Swaroop obtained his Ph.D. in Biochemistry at the Indian Institute of Science, Bangalore, India. After his postdoctoral training at Yale University, he joined the faculty at the University of Michigan in the Departments of Ophthalmology and in Human Genetics in 1990 and held the Harold F. Falls Collegiate Professorship from 2003-07. Dr. Swaroop was recruited to establish Neurobiology-Neurodegeneration and Repair Laboratory at the National Eye Institute, NIH, in 2007 to advance research in all aspects of retinal biology, disease and therapies.
The studies in Swaroop laboratory have focused primarily on genetic and epigenetic regulation of photoreceptor development and aging, genetics of inherited retinal diseases and of age-related macular degeneration, and design of new therapeutic paradigms using cell, gene or small molecule-based approaches.
Dr. Swaroop is leader in the field of retinal development and degeneration and has received many awards for his contributions. He has published almost 350 peer-reviewed articles and reviews (Scopus h-index=71), and delivered 300 invited lectures including named and keynote talks worldwide. Dr. Swaroop routinely reviews for many prestigious journals, contributes to institutional committees for promotions and tenure, and evaluates grants for national and international funding agencies.
1. Age-Related Macular Degeneration: Epidemiology and Clinical Aspects.- 2. Ocular Imaging for Enhancing the Understanding, Assessment, and Management of Age-Related Macular Degeneration.- 3. Histopathology of Age-Related Macular Degeneration and Implications for Pathogenesis and Therapy.- 4. Bruch's Membrane and the Choroid in Age-Related Macular Degeneration.- 5. Innate Immunity in Age-Related Macular Degeneration.- 6. Immunological Aspects of Age-Related Macular Degeneration.- 7. AMD Genetics: Methods and Analyses for Association, Progression, and Prediction.- 8. Making Biological Sense of Genetic Studies of Age-Related Macular Degeneration.- Age-Related Macular Degeneration: From Epigenetics to Therapeutic Implications.- 10. Mitochondria: The Retina's Achilles' Heel in AMD.- 11. Cell-Based Therapies for Age-Related MacularDegeneration.- 12. Current Management of Age-Related Macular Degeneration.
| Erscheinungsdatum | 15.04.2021 |
|---|---|
| Reihe/Serie | Advances in Experimental Medicine and Biology |
| Zusatzinfo | X, 314 p. 73 illus., 61 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 178 x 254 mm |
| Gewicht | 809 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Augenheilkunde |
| Studium ► 1. Studienabschnitt (Vorklinik) ► Physiologie | |
| Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
| Schlagworte | Age-related macular degeneration • Choroid • Clinical Diagnosis • epidemiology • epigenetics • immunology • Incurable blindness • Ocular Imaging • proteostasis • Stem Cell based Therapies |
| ISBN-10 | 3-030-66013-3 / 3030660133 |
| ISBN-13 | 978-3-030-66013-0 / 9783030660130 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
